tert-butyl (6-cyanonaphthalen-2-yl)carbamate | 869114-69-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: tert-butyl (6-cyanonaphthalen-2-yl)carbamate
• 英文别名: tert-butyl 6-cyano-2-naphthylcarbamate；tert-butyl N-(6-cyanonaphthalen-2-yl)carbamate
• CAS: 869114-69-2
• 化学式: C₁₆H₁₆N₂O₂
• 分子量: 268.315
• InChiKey: RQTQAOLCWZQRSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (6-cyanonaphthalen-2-yl)carbamate 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 生成 6-氨基萘-2-甲腈
  参考文献：
  名称：

  Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase

  摘要：

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-RT) are reported that incorporate a 7-in-dolizinylamino or 2-naphthylamino substituent on a pyrimidine or 1,3,5-triazine core. The most potent compounds show below 10 nanomolar activity towards wild-type HIV-1 and variants bearing Tyr181Cys and Lys103Asn/Tyr181Cys resistance mutations. The compounds also feature good aqueous solubility. Crystal structures for two complexes enhance the analysis of the structure-activity data. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.06.074
• 作为产物：
  描述：

  6-溴-2-萘甲醛 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 sodium azide 、 三氟甲磺酸 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 17.0h， 生成 tert-butyl (6-cyanonaphthalen-2-yl)carbamate
  参考文献：
  名称：

  Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase

  摘要：

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-RT) are reported that incorporate a 7-in-dolizinylamino or 2-naphthylamino substituent on a pyrimidine or 1,3,5-triazine core. The most potent compounds show below 10 nanomolar activity towards wild-type HIV-1 and variants bearing Tyr181Cys and Lys103Asn/Tyr181Cys resistance mutations. The compounds also feature good aqueous solubility. Crystal structures for two complexes enhance the analysis of the structure-activity data. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.06.074

文献信息

• Nitro <i>seco</i> Analogues of the Duocarmycins Containing Sulfonate Leaving Groups as Hypoxia-Activated Prodrugs for Cancer Therapy
  作者：Ralph J. Stevenson、William A. Denny、Moana Tercel、Frederik B. Pruijn、Amir Ashoorzadeh

  DOI：10.1021/jm201717y

  日期：2012.3.22

  of 19 (5-nitro-2,3-dihydro-1H-benzo[e]indol-1-yl)methyl sulfonate prodrugs containing sulfonate leaving groups and 7-substituted electron-withdrawing groups is reported. These were designed to undergo hypoxia-selective metabolism to form potent DNA minor groove-alkylating agents. Analogues 17 and 24, containing the benzyl sulfonate leaving group and a neutral DNA minor groove-binding side chain, displayed

  报道了19（5-硝基-2,3-二氢-1 H-苯并[ e ]吲哚-1-基）甲基磺酸盐前药的合成，该药物含有磺酸盐离去基团和7-取代的吸电子基团。这些被设计用于进行缺氧选择性代谢，以形成有效的DNA小沟烷基化剂。类似物17和24，包含磺酸苄酯离去基团和中性DNA小沟结合侧链，在体外抗增殖试验中显示HT29人癌细胞的缺氧细胞毒性比（HCR）> 1000。四个类似物在一组八种人类癌细胞系中维持较大的HCR。在克隆形成分析中，19HT29细胞的HCR显示为4090。还制备了十种可溶性磷酸盐前药，并以无毒剂量在体内，单独或与放射联合在SiHa人肿瘤异种移植物中进行了评估。化合物34和39的缺氧log 10细胞杀伤（LCK）分别为1.78和2.71，与先前报道的氯化物或溴化物类似物具有同等或更高的活性，因此显示出作为缺氧激活的前药的杰出前景。
• Liquid-Crystal Aligning Agent, Liquid-Crystal Alignment Film Comprising the Same, and Liquid-Crystal Element
  申请人：Tsutsui Kimiaki

  公开号：US20070224370A1

  公开（公告）日：2007-09-27

  It is to provide a liquid crystal aligning agent capable of forming a liquid crystal alignment film having favorable electrical characteristics, and excellent in the storage stability and the productivity. A liquid crystal aligning agent comprising at least one member selected from a polyamic acid obtained by polymerization of a diamine component with a tetracarboxylic dianhydride component, and a polyimide obtained by cyclodehydration of the polyamic acid, characterized in that the diamine component contains at least one of diamines represented by the following formula [1]: H 2 N-A-R—NH 2 [1] wherein A is a bivalent organic group comprising a benzene ring or an aromatic condensed ring, provided that one or more optional hydrogen atoms in the benzene ring or the aromatic condensed ring may be substituted by a monovalent organic group other than an amino group, and R is a C 1-10 bivalent saturated hydrocarbon group.

  本发明旨在提供一种液晶取向剂，能够形成具有良好电学特性、储存稳定性和生产率优异的液晶取向膜。液晶取向剂包括至少一种由二胺组分与四羧酸二酐组分聚合得到的聚酰胺酸和由聚酰胺酸环状脱水得到的聚酰亚胺，其特征在于二胺组分中包含下式[1]所表示的二胺之一：H2N-A-R—NH2[1]其中，A是一个双价的有机基团，包括苯环或芳香环，并且苯环或芳香环中的一个或多个可选氢原子可以被除氨基以外的一价有机基团取代，R是一个C1-10双价饱和碳氢基团。
• Nitrobenzindoles and Their use in Cancer Therapy
  申请人：Denny William Alexander

  公开号：US20080119442A1

  公开（公告）日：2008-05-22

  The present invention relates generally to nitro-1,2-dihydro-3H-benzo[e]indoles and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及硝基-1,2-二氢-3H-苯并[e]吲哚及其相关类似物，其制备方法以及其作为低氧选择性药物和放射增敏剂在癌症治疗中的使用，可以单独使用或与辐射和/或其他抗癌药物联合使用。
• Nitrobenzindoles and their use in cancer therapy
  申请人：Auckland Uniservices Limited

  公开号：US07718688B2

  公开（公告）日：2010-05-18

  The present invention relates generally to nitro-1,2-dihydro-3H-benzo[e]indoles and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及硝基-1,2-二氢-3H-苯并[e]吲哚及其相关类似物，其制备方法以及它们作为治疗癌症的低氧选择性药物和放射增敏剂的用途，无论是单独使用还是与放射线和/或其他抗癌药物联合使用。
• WO2006/43839
  申请人：——

  公开号：——

  公开（公告）日：——